Lameris, Roeland, Shahine, Adam, Pellicci, Daniel G., Uldrich, Adam P., Gras, Stephanie, Le Nours, Jérôme, Groen, Richard W. J., Vree, Jana, Reddiex, Scott J. J., Quiñones-Parra, Sergio M., Richardson, Stewart K., Howell, Amy R., Zweegman, Sonja, Godfrey, Dale I., de Gruijl, Tanja D., Rossjohn, Jamie ![]() |
Abstract
Antibody-mediated modulation of major histocompatibility complex (MHC) molecules, or MHC class I-like molecules, could constitute an effective immunotherapeutic approach. We describe how single-domain antibodies (VHH), specific for the human MHC class I-like molecule CD1d, can modulate the function of CD1d-restricted T cells and how one VHH (1D12) specifically induced strong type I natural killer T (NKT) cell activation. The crystal structure of the VHH1D12-CD1d(α-GalCer)-NKT T-cell receptor (TCR) complex revealed that VHH1D12 simultaneously contacted CD1d and the type I NKT TCR, thereby stabilizing this interaction through intrinsic bispecificity. This led to greatly enhanced type I NKT cell-mediated antitumor activity in in vitro, including multiple myeloma and acute myeloid leukemia patient-derived bone marrow samples, and in vivo models. Our findings underscore the versatility of VHH molecules in targeting composite epitopes, in this case consisting of a complexed monomorphic antigen-presenting molecule and an invariant TCR, and represent a generalizable antitumor approach.
Item Type: | Article |
---|---|
Date Type: | Published Online |
Status: | Published |
Schools: | Medicine |
Publisher: | Nature Research |
ISSN: | 2662-1347 |
Date of Acceptance: | 5 August 2020 |
Last Modified: | 10 Nov 2022 11:23 |
URI: | https://orca.cardiff.ac.uk/id/eprint/150332 |
Citation Data
Cited 25 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |